Business Wire

Merz Therapeutics’ XEOMIN® (incobotulinumtoxinA) receives new therapeutic indication for the United Kingdom

Share

Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the use of XEOMIN® for the treatment of focal spasticity of the lower limb affecting the ankle joint. The approval, which previously included upper limb spasticity, has now been extended, enabling Merz Therapeutics to offer holistic support to people in the UK living with spasticity who require comprehensive treatment.

“The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve. With the UK becoming the second market, following Japan, to grant approval for the treatment of lower limb spasticity, affecting the ankle joint, it establishes the UK as the pioneering European country in this area. This approval supports our strong commitment to bringing better outcomes to more patients,” says Stefan König, CEO Merz Therapeutics.

Enabling holistic treatment for people living with spasticity

Lower limb spasticity is a consequence of upper motor neuron damage as may occur following e.g. a stroke. Each year, around 41,800 people in England have a stroke that results in spasticity, approximately 66 % of which suffer from spasticity in the ankle.1 XEOMIN ® with the active ingredient incobotulinumtoxinA is injected intramuscularly to improve tone. Appropriately qualified healthcare practitioners can now use XEOMIN ® to treat lower and upper limbs individually or concomitantly, adjusting the dosage as needed.

John Lambert, Country Manager of Merz Therapeutics UK & Ireland: “This new therapeutic indication supports an extension of the benefit XEOMIN® can bring in the treatment of spasticity. We are very proud that we can now offer an alternative product to help patients in the UK.”

With the new therapeutic indication, the maximum dose of XEOMIN® for the treatment of the lower limb is 400 units per injection. For the combined treatment of upper and lower limb spasticity, the maximum dose per administration is 500 units for the first injection and rising to 600 units for following injections. Accepting that patients should always be administered the lowest effective dose possible, with an increase in total dose patients can now be treated with XEOMIN® for more patterns of spasticity simultaneously than before this new indication. The dosing interval should be at least 12 weeks. The therapeutic indication is based on trial data from Japan, where XEOMIN ® was also approved for treatment of the lower limb region in 2021.

Going forward, Merz Therapeutics can thus offer UK patients being treated for their spasticity a more holistic solution for their treatment.

1. National Institute for Health and Care Excellence Draft scope for the proposed appraisal of botulinum toxin type A (Botox, Dysport and Xeomin) for treating upper and lower limb spasticity associated with stroke Issue Date: July 2014. Available at: https://www.nice.org.uk/guidance/gid-tag499/documents/spasticity-after-stroke-botulinum-toxin-type-a-draft-scope-for-consultation-prereferral-july-20142. (Accessed: 02 June, 2023).

About XEOMIN ®

XEOMIN® is effective by weakening the contraction of voluntary muscles. It relieves the muscle tone by inhibiting the release of a neurotransmitter called acetylcholine from the peripheral nerve endings. XEOMIN® is free from complexing proteins and has a low risk of neutralizing antibody formation. XEOMIN® is approved in more than 75 countries worldwide to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm and sialorrhea.

About Merz Therapeutics

Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.

Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.

Please visit www.merztherapeutics.com

About Merz

Merz Group is a global, diversified company with its headquarters in Frankfurt, Germany. Its commitment to innovation, long-term perspective, and focus on profitable growth depict the privately owned company that has been around for more than 110 years. Merz Group has the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate and Financial Investments. The company employs 3,969 people in 28 countries worldwide.

To learn more, please visit www.merz.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Merz Therapeutics GmbH
Agnes Tesch
Global Communications
+49 69 1503 2129
agnes.tesch@merz.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Valeo Foods Group Acquires Freddi Dolciaria S.p.A, Enhancing its Position in the Italian Bakery Sector2.5.2025 11:00:00 EEST | Press release

Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the Italian sweet bakery producer Freddi Dolciaria S.p.A (“Freddi”), accelerating growth in South-West European region and enhancing its position in the bakery sector. Freddi is an Italian sweet bakery company founded in 1949 by Luigi Freddi and headquartered in Castiglione delle Stiviere, Italy. Specialising in sponge cakes, Freddi has an established presence in both the Italian retail and international markets, with an annual turnover approaching €20 million and 48 employees. This acquisition strengthens Valeo Foods Group’s position in the packaged wafers, cakes, and biscuits category, complementing the existing Balconi business across Southern Europe and international markets. The integration of Freddi is expected to drive sustainable, profitable growth while enhancing production capacity and operational efficiency. It also reinforces Valeo’s continued expansion in th

Perma-Pipe International Holdings, Inc. Announces Fourth Quarter and Fiscal 2024 Financial Results1.5.2025 23:24:00 EEST | Press release

Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the fourth quarter and 2024 fiscal year ended January 31, 2025. “Sales for the fourth quarter and full year 2024 show moderate growth and were $45.0 million and $158.4 million, resulting in increases of $4.8 million and $7.7 million, compared to the prior year. Income before taxes was $5.3 million and $18.5 million in the fourth quarter and for the full year 2024, which increased by $2.1 million and $8.6 million, compared to the prior year. This significant increase was a result of our focus on higher margin products and services that contributed to improved margin performance. Net income after taxes and minority interest was $1.5 million and $9.0 million in the fourth quarter and for the full year 2024. Although 2024 net income was a decrease of $1.5 million, compared to $10.5 million last year, the reduction was due to a one-time non-cash tax benefit of $5.9 million in the prior year after be

IFF Declares Dividend for Second Quarter 20251.5.2025 23:15:00 EEST | Press release

IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20250501776988/en/

Rimini Street Announces Fiscal First Quarter 2025 Financial and Operating Results1.5.2025 23:01:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501664008/en/ Select First Quarter 2025 Financial Results Revenue was $104.2 million for the 2025 first quarter, a decrease of 2.4% compared to $106.7 million for the same period last year. U.S. revenue was $50.1 million for the 2025 first quarter, a decrease of 6.9% compared to $53.8 million for the same period last year. International revenue was $54.1 million for the 2025 first quarter, an increase of 2.2% compared to $52.9 million for the same period last year. Subscription revenue was $99.0 million, which accounted for 95.0% of total revenue for the 2025 first quarter, compared to subscription rev

Textron Aviation Calls on Cessna, Beechcraft and Hawker Owners to Transport Athletes to the 2026 Special Olympics USA Games1.5.2025 18:31:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the coordination of the ninth Special Olympics Airlift, a monumental event aimed at transporting hundreds of athletes and coaches across country to the 2026 Special Olympics USA Games in Minnesota’s Twin Cities. The company is calling on Cessna, Beechcraft and Hawker aircraft owners and operators to come together on Friday, June 19, 2026, and Saturday, June 27, 2026, to enable champions from all corners of the nation to travel to and from the host city, regardless of financial or logistical challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430812758/en/ Textron Aviation Inc. announced the coordination of the ninth Special Olympics Airlift, a monumental event aimed at transporting hundreds of athletes and coaches across country to the 2026 Special Olympics USA Games in Minnesota’s Twin Cities. (Photo credit: Textron Aviation) The Special Oly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye